Healthcare provider profile · identity verified

Luhua Cheng, MD

Internal Medicine · SAN JOSE, CA · NPI 1598823890

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	397	116
Amlodipine Besylate	Amlodipine Besylate	335	107
Metformin Hcl	Metformin Hcl	269	82
Losartan Potassium	Losartan Potassium	216	68
Levothyroxine Sodium	Levothyroxine Sodium	195	48
Glipizide	Glipizide	156	39
Hydrochlorothiazide	Hydrochlorothiazide	140	41
Gabapentin	Gabapentin	136	41
Jardiance	Empagliflozin	135	35
Simvastatin	Simvastatin	124	37
Omeprazole	Omeprazole	118	45
Metoprolol Tartrate	Metoprolol Tartrate	115	32
Fluticasone Propionate	Fluticasone Propionate	110	51
Fosinopril Sodium	Fosinopril Sodium	99	30
Tamsulosin Hcl	Tamsulosin Hcl	94	27
Triamcinolone Acetonide	Triamcinolone Acetonide	79	34
Furosemide	Furosemide	77	25
Diclofenac Sodium	Diclofenac Sodium	73	33
Mounjaro	Tirzepatide	68	suppressed
Baclofen	Baclofen	64	21
Alendronate Sodium	Alendronate Sodium	59	16
Trulicity	Dulaglutide	58	suppressed
Tradjenta	Linagliptin	56	17
Ozempic	Semaglutide	55	11
Pantoprazole Sodium	Pantoprazole Sodium	55	16
Ibuprofen	Ibuprofen	48	23
Albuterol Sulfate Hfa	Albuterol Sulfate	46	20
Lisinopril	Lisinopril	46	18
Ultra-Fine Nano Pen Needle	Pen Needle, Diabetic	46	11
Atenolol	Atenolol	45	16
Benazepril Hcl	Benazepril Hcl	45	16
Hydroxyzine Hcl	Hydroxyzine Hcl	44	13
Fenofibrate	Fenofibrate Nanocrystallized	43	14
Carvedilol	Carvedilol	40	suppressed
Eliquis	Apixaban	38	suppressed
Finasteride	Finasteride	38	13
Famotidine	Famotidine	37	17
Hydralazine Hcl	Hydralazine Hcl	35	suppressed
Fenofibrate	Fenofibrate	31	suppressed
Metoprolol Succinate	Metoprolol Succinate	31	suppressed
Ultra-Fine Short Pen Needle	Pen Needle, Diabetic	27	suppressed
Trazodone Hcl	Trazodone Hcl	26	suppressed
Acetaminophen-Codeine	Acetaminophen With Codeine	24	suppressed
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	23	suppressed
Nortriptyline Hcl	Nortriptyline Hcl	23	suppressed
Montelukast Sodium	Montelukast Sodium	22	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	22	suppressed
Spironolactone	Spironolactone	22	suppressed
Meclizine Hcl	Meclizine Hcl	21	suppressed
Novolog Mix 70-30 Flexpen	Insulin Aspart Prot/Insuln Asp	21	suppressed
Allopurinol	Allopurinol	20	suppressed
Glipizide Er	Glipizide	20	suppressed
Naproxen	Naproxen	20	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	20	suppressed
Pravastatin Sodium	Pravastatin Sodium	20	suppressed
Humalog Kwikpen U-100	Insulin Lispro	19	suppressed
Paroxetine Hcl	Paroxetine Hcl	18	suppressed
Semglee (Yfgn) Pen	Insulin Glargine-Yfgn	18	suppressed
Metformin Hcl Er	Metformin Hcl	17	suppressed
Rybelsus	Semaglutide	17	suppressed
Tresiba Flextouch U-200	Insulin Degludec	17	suppressed
Arnuity Ellipta	Fluticasone Furoate	15	suppressed
Atrovent Hfa	Ipratropium Bromide	15	suppressed
Clopidogrel	Clopidogrel Bisulfate	15	suppressed
Rosuvastatin Calcium	Rosuvastatin Calcium	15	suppressed
Toujeo Max Solostar	Insulin Glargine,hum.Rec.Anlog	15	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	14	suppressed
Prednisone	Prednisone	14	suppressed
Xarelto	Rivaroxaban	14	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	13	suppressed
Tramadol Hcl	Tramadol Hcl	13	suppressed
Cephalexin	Cephalexin	12	11
Loperamide	Loperamide Hcl	12	suppressed
Mirtazapine	Mirtazapine	12	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	12	suppressed
Azelastine Hcl	Azelastine Hcl	11	suppressed
Celecoxib	Celecoxib	11	suppressed
Novolog Flexpen	Insulin Aspart	11	suppressed
Sertraline Hcl	Sertraline Hcl	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error